Clinical Trial

Motor Evoked Potential and Cortical Silent Period in Migraine

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to assess the level of inhibitory control in the motor cortex of migraine patients using objective and non-invasive methods. To this end, Motor Evoked Potential (MEP) and Cortical Silence Period (CSP) parameters obtained using Transcranial Magnetic Stimulation (TMS) will be measured and comparisons will be made between migraine patients and healthy controls. Since CSP duration is used specifically in the evaluation of GABA-B-mediated inhibitory mechanisms, it has the potential to directly measure the effect of migraine on cortical inhibition.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-21.
Trial Details
NCT Number NCT07250464
Lead Sponsor Istanbul Gelisim University
Conditions Migraine, Healty Controls
Enrollment 20 participants
Start Date 2025-12-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-28